Please sign in to follow a disease.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Clinical trials for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) explained in plain language.
Never miss a new study
Get alerted when new Blastic plasmacytoid dendritic cell neoplasm (BPDCN) trials appear
Sign up with your email to follow new studies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a targeted therapy tame a rare blood cancer in everyday practice?
Disease control Recruiting nowThis registry study is following adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, who are being treated with the drug tagraxofusp (ELZONRIS) in routine clinical care. The goal is to see how effective the treatment is at achievi…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Promising combo targets rare blood cancer in early trial
Disease control Recruiting nowThis study tests a two-drug combination (tagraxofusp and venetoclax) in adults with a rare and aggressive blood cancer called BPDCN who have not had prior treatment. The main goal is to see if the combination can achieve complete remission after 3 months. Depending on results, pa…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can chemotherapy tame a rare blood cancer? a look back at Real-World outcomes
Knowledge-focused Recruiting nowThis study looks back at the medical records of about 140 people with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received chemotherapy as their first treatment. The goal is to see how effective and safe different chemotherapy regimens are …
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Stemline Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Rare cancer registry aims to unlock treatment secrets
Knowledge-focused Recruiting nowThis study creates a worldwide registry for people diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare blood cancer. Researchers will collect information on how the disease presents, how it is treated, and what happens to patients over time. The goal …
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Immune Oncology Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC